ストックスクリーナーアプリを入手
1.21
1.63%
-0.02
前日終値:
$1.23
開ける：
$1.24
24時間の取引高:
29,831
Relative Volume:
0.25
時価総額：
$36.52M
収益：
-
当期純損益:
$-60.70M
株価収益率:
-0.5931
EPS:
-2.04
ネットキャッシュフロー:
$-61.05M
1週間 パフォーマンス:
+0.83%
1か月 パフォーマンス:
-5.47%
6か月 パフォーマンス:
+21.00%
1年 パフォーマンス:
-46.70%
1日の値動き範囲:
$1.195
$1.24
1週間の範囲:
$1.15
$1.24
52週間の値動き範囲:
$0.87
$3.07
An 2 Therapeutics Inc Stock (ANTX) Company Profile
名前
An 2 Therapeutics Inc
セクター
電話
(650) 331-9090
住所
1800 EL CAMINO REAL, SUITE D, MENLO PARK
ANTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
1.21 | 36.21M | 0 | -60.70M | -61.05M | -2.04 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-09 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2024-08-09 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-07-03 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-04-02 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2024-02-13 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-02-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-12 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-02-12 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-01-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
すべてを表示
An 2 Therapeutics Inc (ANTX) 最新ニュース
Nuvig Therapeutics Announces First Patient Dosed in Phase 2 CIDP Trial of NVG-2089 and Presentation of Phase 1 Data - Business Wire
Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen - Quantisnow
Cognition Therapeutics, Inc. (CGTX) Reports Topline Results Showing Oral CT1812 Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - StreetInsider
Aligos Therapeutics, Inc. SEC 10-Q Report - TradingView
Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? - Yahoo Finance
PTC Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
PTC Therapeutics, Inc. Announces Results from the Phase 2 PIVOT-HD Study of PTC518 in Stage 2 and Stage 3 Huntington's Disease Patients - marketscreener.com
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF - The Victoria Advocate
Relmada Therapeutics, Inc. Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - marketscreener.com
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - Quantisnow
Relmada Therapeutics Reports 'Positive' Phase 2 Data for Bladder Cancer Treatment - marketscreener.com
Protara Therapeutics Shares Positive Phase 2 Interim Results Of TARA-002 In Patients With NMIBC - Nasdaq
Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering - PR Newswire
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia - Business Wire
Xilio Therapeutics to Present Updated Phase 2 Data for - GlobeNewswire
Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting - Yahoo Finance
Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025 - Yahoo Finance
Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) - GlobeNewswire
TransCode Therapeutics Faces Crucial Reverse Split Decision as Special Meeting Falls Short of Quorum - Stock Titan
Coya Therapeutics, Inc. Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death) - marketscreener.com
Viking Therapeutics (NasdaqCM:VKTX) Completes Enrollment For Phase 2 Trial Of VK2735 - Yahoo Finance
Verve Therapeutics Announces Positive Initial Data from the - GlobeNewswire
Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance - GlobeNewswire
Cyrano Therapeutics Completes Enrollment in Phase 2 FLAVOR Trial of CYR-064 for Post-Viral Smell Loss - Yahoo Finance
KSQ Therapeutics Announces First Patient Dosed in Phase 1/2 - GlobeNewswire
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data For Lx2006 In Friedreich Ataxia Cardiomyopathy Supporting Advancement To Registrational Study - MarketScreener
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study - GlobeNewswire
NMRA Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit - The Malaysian Reserve
Alaunos Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting - Yahoo Finance
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance - GlobeNewswire
Intellia Therapeutics Announces First Patient Dosed in the - GlobeNewswire
Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy - GlobeNewswire
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program - GlobeNewswire
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) - BioSpace
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights - Yahoo Finance
Tenaya Therapeutics Announces Late Breaker Presentation - GlobeNewswire
Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday? - Yahoo Finance
Yoda Therapeutics Announces First Patient Dosed in Phase 2 Trial of YA-101 for Multiple System Atrophy - BioSpace
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time - Yahoo Finance
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - Quantisnow
Major Milestone: Viking's Oral Weight Loss Drug Advances with 280-Patient Phase 2 Trial - Stock Titan
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 - Yahoo Finance
Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. - The Manila Times
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025 - GlobeNewswire
Cognition Therapeutics, Inc. Reports Positive Phase 2 Results for Zervimesine in Dementia with Lewy Bodies and Alzheimer's Disease, Plans Advancement to Late-Stage Trials - Nasdaq
Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update - GlobeNewswire
Tenaya Therapeutics Announces Late Breaker and New Data - GlobeNewswire
EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors - Yahoo Finance
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Ex - GlobeNewswire
Allarity Therapeutics Announces Presentation of Phase 2 - GlobeNewswire
An 2 Therapeutics Inc (ANTX) 財務データ
収益
当期純利益
現金流量
EPS
An 2 Therapeutics Inc (ANTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Chanda Sanjay | Chief Development Officer |
Jan 03 '25 |
Sale |
1.34 |
2,957 |
3,965 |
29,824 |
| Prior Stephen David | Chief Strategy Officer |
Jan 03 '25 |
Sale |
1.34 |
2,029 |
2,721 |
33,313 |
| Eizen Joshua M | See Remarks |
Jan 03 '25 |
Sale |
1.34 |
9,663 |
12,958 |
116,672 |
| Readnour Robin Shane | Director |
Dec 09 '24 |
Buy |
1.43 |
30,772 |
43,984 |
647,573 |
| Readnour Robin Shane | Director |
Dec 06 '24 |
Buy |
1.45 |
19,228 |
27,795 |
629,090 |
| Readnour Robin Shane | Director |
Dec 10 '24 |
Buy |
1.49 |
10,000 |
14,930 |
652,573 |
| Readnour Robin Shane | Director |
Nov 27 '24 |
Buy |
1.42 |
50,000 |
70,840 |
622,573 |
| Readnour Robin Shane | Director |
Nov 26 '24 |
Buy |
1.39 |
25,000 |
34,845 |
597,573 |
| Zakrzewski Joseph S | Director |
Nov 27 '24 |
Buy |
1.40 |
2,000 |
2,800 |
125,199 |
| Readnour Robin Shane | Director |
Nov 19 '24 |
Buy |
1.04 |
150,000 |
155,258 |
560,073 |
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):